 |
|
|
| |
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB)
Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 144 Results
|
| |
| |
Reported by Jules Levin
14th European AIDS Conference
October 16-19, 2013, Brussels, Belgium
N Clumeck1, J-M Molina2, K Henry3, J Gathe4, JK Rockstroh5, E DeJesus6,
X Wei7, K White7, M Fordyce7, MS Rhee7, J Szwarcberg7
1St Pierre University Hospital, Brussels, Belgium; 2Saint Louis Hospital, Paris, France; 3Hennepin County Medical Center, Minneapolis, MN, US; 4Therapeutic Concepts P.A., Houston, TX, US; 5University of Bonn, Bonn, Germany; 6Orlando Immunology Center, Orlando, FL, US; 7Gilead Sciences, Foster City, CA, US
|
| |
|
|
|
|
|
